World Antibiotics Market

World Antibiotics Market

This report analyzes the worldwide markets for Antibiotics in US$ Billion. The Major product segments Analyzed are Penicillin, Cephalosporins, Macrolides, Quinolones, Carbapenems, and Other Antibiotics (Aminoglycosides, Tetracyclines, Sulfonamides, Mupirocin, Glycopeptides, Synercid, and Oxazolidinones). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 204 companies including many key and niche players worldwide such as Abbott Laboratories, MiddleBrook™ Pharmaceuticals, Inc., Bayer HealthCare AG, Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson, Kyorin Pharmaceutical Co., Ltd., LG Life Sciences Limited, MiddleBrook™ Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pliva d.d., Roche, Sanofi-Aventis SA, Takeda Pharmaceutical Company, Ltd., Toyama Chemical Co., Ltd., and Wyeth Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

ANTIBIOTICS MCP-1705
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-2
Product Definitions and Scope of Study I-3
Penicillin I-3
Cephalosporins I-4
Macrolides I-4
Quinolones I-4
Carbapenems I-4
Other Antibiotics I-4
Aminoglycosides I-4
Tetracyclines I-4
Sulfonamides I-4
Mupirocin I-5
Glycopeptides I-5
Synercid I-5
Oxazolidinones I-5
Linezolid I-5


II. EXECUTIVE SUMMARY

1. Industry Overview II-1
Antibiotic Resistance and Generic Competition to Impact Long
Term Growth II-1
Current & Future Analysis II-1

2. Market Dynamics II-2
Anti-Bacterials Segment Drives Global Anti-Infectives Market II-2
Antibiotic Resistance - A Primary Growth Inhibitor II-2
Antibiotic-Resistant Bacteria by Type II-2
Patent Expiries Commoditize Antibiotics II-3
Patent Expiries of Leading Drugs in the Recent Past, Current,
and Future II-3
Anti-MRSA Antibiotics Find Their Way . II-3
Table 1: Estimated Revenues Generated by Leading MRSA
Antibiotic Drugs in 2005 (includes corresponding Graph/Chart) II-4
Key Antibiotics in Pipeline II-4

3. Competition II-5
Highly Competitive Market II-5
Table 2: Leading Players in the Worldwide Antibiotics Market
(2006): Percentage Breakdown by Value Sales for Pfizer, Glaxo
Smithkline, Sanofi-aventis, Johnson & Johnson, Bayer, Abbott,
Wyeth, and Others (includes corresponding Graph/Chart) II-5
GlaxoSmithKline - The Undisputed Leader of Penicillin Market II-5
Table 3: Worldwide Leading Antibiotics within Penicillin
Class (2005 & 2006): Percentage Breakdown by Value for
Augmentin, Zosyn/Tazocin, Amoxil, and Others (includes
corresponding Graph/Chart) II-6
GlaxoSmithKline Leads Cephalosporin Market II-6
Table 4: Worldwide Leading Antibiotics within Cephalosporin
Class (2005 & 2006): Percentage Breakdown by Value for
Rocephin, Ceftin/Zinnat, Flomox, Fortum/Fortaz, Cefzil,
Cefzon, Flumarin, and Others (includes corresponding
Graph/Chart) II-6
Pfizer Dominates Macrolides Market II-7
Table 5: Worldwide Leading Antibiotics within Macrolide Class
(2005 & 2006): Percentage Breakdown by Value for Zithromax,
Klaricid/Biaxin, Ketek, and Others (includes corresponding
Graph/Chart) II-7
Levaquin/Tavanic - The Most Preferred Quinolone Antibiotic II-7
Table 6: Worldwide Leading Antibiotics within Quinolone Class
(2005 & 2006): Percentage Breakdown by Value for
Levaquin/Tavanic, Avelox, Ciprobay/Ciproxin, Cravid, and
Others (includes corresponding Graph/Chart) II-7
Merck Rules Carbapenems Market II-8
Table 7: Worldwide Leading Antibiotics within Carbapenem
Class (2005 & 2006): Percentage Breakdown by Value for
Primaxin, Merrem, Invanz, and Others (includes corresponding
Graph/Chart) II-8

4. Product Overview II-9
Antibiotics - An Introduction II-9
Antibiotic Resistance II-9
ß -Lactams II-10
Classification of Antibiotics II-11
Key Milestones in Antibiotic Development II-11
Antibiotic Types II-11
Penicillin II-11
History II-11
About the Drug II-12
Cephalosporins II-12
Treatment II-12
Effects of the Drug II-13
Macrolides II-13
Treatment II-13
Quinolones II-13
Carbapenems II-14
Other Antibiotics II-14
Aminoglycosides II-14
Treatment II-14
Effects of the Drug II-15
Tetracyclines II-15
Treatment II-15
Effects of the Drug II-16
Sulfonamides II-16
Treatment II-16
Effects of the Drug II-17
Mupirocin II-17
Glycopeptides II-17
Synercid II-17
Oxazolidinones II-18
Linezolid II-18

5. Research Findings II-19
Cephalosporins Effective when Compared to Penicillin II-19
FDA Bans Baytril Antibiotic for Chickens II-19
Erythromycin Along with Some Specific Drugs Increase Risk of
Sudden Death II-19
Rise in Usage of Quinolones for Urinary Tract Infections Leads
to Drug Resistance II-19

6. FDA Approvals/Patents II-20
MiddleBrook Obtains NDA Approval for MOXATAG™ II-20
J&JPRD Seeks FDA Approval for Doripenem Antibiotic II-20
J&JPRD Seeks FDA Approval for Investigational Antibiotic,
Ceftobiprole II-20
GSK Receives Approval for ALTARGO® in Europe II-20
APL Receives FDA Approval for Cefpodoxime Proxetil II-21
Cubist Receives Approval to Market CUBICIN in Canada II-21
Cubist Obtains Approval to Market CUBICIN for Added
Indications in EU II-21
Cubist Gains Approval for CUBICIN in Taiwan and South Korea II-21
Cethromycin Achieves FDA’s Orphan Drug Designation II-21
FDA Approves Wockhardt’s Cefotaxime Injection II-22
FDA Approves Doxycycline Tablets II-22
FDA Approves Clarithromycin II-22
FDA Approves Doxycycline Tablets For The US Market II-22
Johnson & Johnson Applies Doripenem For FDA Approval II-22
FDA Certifies Antibioticos do Brasil’s Plant II-22
FDA Certifies ANDA For Cefdinir Capsules II-22
US FDA Approves Teva’s Cefprozil Tablets II-23
FDA Certifies ANDA for Cephalexin Capsules II-23
American Pharmaceutical Partners Receives FDA Approvals for
Ceftriaxone for Injection, USP II-23
Advancis’s Keflex Receives FDA Approval II-23
Wockhardt Gains Marketing Approval for Cefuroxime axetil in
the US II-23
Wyeth’s Mylotarq Receives Government’s Approval II-23
FDA Approves Generic Version of Zithromax II-24
Pfizer Wins FDA Approval for Zmax™ II-24
Venus Remedies Files Second PCT for New Cephalosporins II-24
Falcon Gains US FDA Approval for its Generic Anti-Infective
Solution II-24
Cadilla Receives FDA Approval to Market Clindamycin II-25

7. Recent Industry Activity II-26
3i to Buy Alpharma Unit II-26
NCPC to Acquire Stake in DSM’s Antibiotics Division II-26
ULL Establishes New Antibiotics Unit in Himachal Pradesh II-26
Biocat to Expand Presence in the Indian Market II-26
PRWT Acquires Cherokee Chemical Unit from Merck II-26
CSPC Joins Hands with Indonesian Firms II-27
Nisshin-Kyorin to Merge with Kyorin Pharmaceutical II-27
Schering-Plough Acquires Organon BioSciences II-27
GSK & Anacor Partner for Boron Chemistry-Based Antibiotics
and Antivirals II-27
Iroko Bags Canadian Rights to Vancocin® II-28
Cubist Licenses CUBICIN Rights to Merck II-28
Sagent Partners with Astral to Develop Injectable Antibiotics II-28
MR Healthcare to Manufacture New Antibiotics & Medicines II-28
Livzon Synthetic to Acquire Antibiotic Intermediate from Jiaozuo II-29
C&O Pharmaceutical to Distribute Meiact in China II-29
Bioton Signs Deal to Market Antibiotics in Russia II-29
Toyama Gains Marketing Approval for Geninax® in Japan II-29
Forest Laboratories Acquires Cerexa II-29
Oscient Modifies Licensing Agreement With LG Life Sciences II-29
Orchid Sign Licensing & Distribution Pact With Actavis II-30
Forest Laboratories Revokes Partnership With Replidyne II-30
SRI and Blanca Collaborate To Develop & Test Carbacephem II-30
AstraZeneca To Expand Research Center For Antibiotics II-30
Jade Pharmaceutical Begins Levofloxacin’s Production in China II-30
Reyoung To Start Antibiotic Production At New Facility II-31
Toyama Begins T-705 Clinical Trials II-31
SmPC For Sanofi-Aventis’ Ketek® Updated II-31
Lupin Receives Approval for Cefpodoxime Proxetil Antiobiotic
Tablets in France II-31
Antibiotice Plans To Infuse Funds For Antibiotics Production II-31
UAE Approves Pfizer’s Zithromax SD II-31
Premier Takes Over Cereplex II-31
Laboratorios Roemmers Acquires Argentine Pharmaceutical’s
Business II-32
Ranbaxy Adds Be-Tabs II-32
AstraZeneca Purchases Vancocin® From Eli Lilly II-32
Ranbaxy Laboratories Limited Acquires Ethimed NV II-32
Ranbaxy Laboratories Limited Acquires Terapia SA II-32
Ranbaxy Italia Acquires Allen Generic Business of GlaxoSmithKline II-33
Connetics Acquires Sales Organization of PediaMed II-33
Wyeth Increases Stake in Wyeth KK to 80% II-33
Sankyo Pharma, Daiichi Medical Research and Daiichi
Pharmaceutical Merge II-34
Merck & Co. and Paratek Sign Development & License Pact II-34
Wakunga and Rib-X Sign Licensing Pact II-34
Pfizer Settles Infringement Lawsuit With Teva II-34
Astellas Extends Agreement With Theravance II-34
Astellas and Theravance Sign Collaboration Agreement II-35
Cubist and AstraZeneca Sign License Pact II-35
Astellas Pharma and Sanofi-Aventis Revoke Marketing Pact II-35
Achaogen Bags Licensing Agreement from Isis II-35
Pfizer Bags Rights from Oscient to Market Antibiotic in Mexico II-35
Replidyne Enters into Licensing Agreement with Forest
Laboratories II-35
Toyama Chemical Co Ltd Enters into Licensing Agreement with
Astellas Pharma II-36
AVAS’ Majority Stake To Be Sold II-36
NIH Grants US$3 Million To PolyMedix For Antibiotics II-36
Wyeth’s Tygacil Achieves European Approval II-36
Chiron’s Cubicin® Receives Marketing Grant In The EU II-37
Vietnam Bans Antibiotics In Aquaculture II-37
Sance Pharmaceuticals Establishes Sance Laboratories II-37
Caps Holdings Plans to Re-enter Penicillin Market II-37
Alkem Establishes Sterile Cephalosporin Unit II-37
Novartis Completes Chiron Acquisition II-37
Toyama Submits New Drug Application For Quinolone Antibiotic
Compound II-37
China Pharma Receives GMP Certification For Cephalosporin
Antibiotic Production II-38
Venus Remedies Files For FDC Approval II-38
Sankyo Acquires rival Daiichi Pharmaceutical for US$ 7 Billion II-38
Daiichi Pharmaceutical Takes Over Daiichi Suntory Pharma II-38
Pfizer Acquires Idun Pharmaceuticals II-38
Pfizer Acquires Vicuron Pharmaceuticals II-39
Pfizer Acquires Bioren II-39
Novartis Acquires Eon Labs II-39
Kyorin Pharmaceutical Acquires Stake in Toyo Pharmar II-40
Targanta Acquires InterMune’s Late-Stage Antibiotic II-40
Novartis Acquires Hexal II-40
TB Alliance and Bayer Partner in Clinical Trials II-41
SBC Communications Enters into Agreement with Pfizer for
Managed Voice Services II-41
Vicuron Extends Oral Antibiotics Development Agreement With
Pfizer II-42
Orchid Chemicals Signs Distribution Agreement with Mayne Pharma II-42
Cubist Pharmaceuticals Inks Agreement with ACS Dobfar II-42
Orchid Chemicals Inks Marketing Agreement with Alpharma II-42
Lupin and DSM Anti-Infectives Sign Agreement to Market
Cephalosporins II-42
Ranbaxy to Market P&G’s Generic Drug II-43
Nectar Expands Capacity II-43
Novartis Establishes Novartis Holding Japan II-43
Sun Pharma Acquires Phlox Pharma II-43
Kyorin Takes Over ActivX II-43
Advancis Acquires Lilly’s Keflex Brand II-43
Enanta Enters into Partnership with Shionogi & Co. II-44
Toyama Signs Collaborative Agreement with Glaxo to Develop
Antibacterial Agents II-44
Enanta and Shionogi Ink an Agreement to Market EP- 013420 II-45
Orchid Inks Agreement with Apotex to Market Generic Antibiotics II-45
Toyama Signs Licensing Agreement for TN-3262a with Dong-A II-45
Toyama Inks License Agreement with Schering for T-3811 II-45
Shionogi Wins Rights to Market Cedax in the US II-46
Connetics Enters Acne Market II-46

8. Product Innovations/Introductions II-47
MIT Scientists Develop a New Antibiotic, Rhodostreptomycin II-47
Watson Pharma Introduces Biaxin XL’s Generic Version II-47
Toyama Launches New Garenoxacin Quinolone Antibiotic II-47
Wockhardt to Introduce Cefprozil in the US II-47
MSD India Launches Invanza in India II-47
Orchid Chemicals to Introduce Three New Drugs in the US II-48
DUSA Pharmaceuticals Releases ClindaReach™ II-48
Mylan Releases Cipro’s Generic Version II-48
Macrolide Antibiotic Developed In the US II-48
University of Michigan Devises NMR Spectroscopy For Antibiotics II-48
Glycopeptide-Cephalosporin Antibiotics Developed In The US II-48
Neosil Tests NEO 101 Antibiotic II-48
New Antibiotic Developed By Canadian Inventors II-49
Abbott Canada Releases FACTIVE® Antibiotic Tablets In Canada II-49
Pencillin Binding Protein Found In Japan II-49
Venus Remedies Releases Mucomelt-Forte II-49
Baxter Launches Injectable Antibiotic, Zithromax II-49
Advancis Releases Keflex (750mg) Capsules II-49
Researchers Develop Antibiotic For MRSA II-50
Wyeth Releases Tygacil In The UK II-50
Nihon Pharmaceutical Releases Clarithomycin Antibiotic II-50
Daiichi Sankyo Engages In Quinolone Antibiotic Development II-50
Shionogi Commercializes Finibax II-50
Sandoz and Nomura Phase4 Ventures Launch Nabriva Therapeutics
Forschungs GmbH II-50
Lilly’s Investigational Cancer Agent Reaches Phase III
Clinical Trial II-50
Idemitsu Technofine Launches Antibacterial Product II-51
Galleon Develops Oral Aminoglycoside Antibiotic II-51
Advancis Introduces Keflex® Powder in the US II-51
Skin Test for Penicillin Comes Back into the Market II-51
Cubist Introduces New Registry Program II-52
Idemitsu Technofine Launches Antibacterial Product II-52

9. Focus on Select Global Players II-53
Abbott Laboratories (USA) II-53
MiddleBrook™ Pharmaceuticals, Inc. (USA) II-53
Bayer HealthCare AG (Germany) II-53
Bristol-Myers Squibb Co. (USA) II-54
Cubist Pharmaceuticals, Inc. (USA) II-54
Daiichi Sankyo Company, Limited (Japan) II-54
Eli Lilly and Co. (USA) II-55
GlaxoSmithKline Plc (UK) II-56
Johnson & Johnson (USA) II-56
Kyorin Pharmaceutical Co., Ltd. (Japan) II-57
LG Life Sciences Limited (Korea) II-57
MiddleBrook™ Pharmaceuticals, Inc. (USA) II-58
Novartis AG (Switzerland) II-58
Pfizer Inc. (USA) II-59
Pliva d.d. (Croatia) II-59
Roche (Switzerland) II-60
Sanofi-Aventis SA (France) II-60
Takeda Pharmaceutical Company, Ltd. (Japan) II-60
Toyama Chemical Co., Ltd. (Japan) II-61
Wyeth Pharmaceuticals, Inc. (USA) II-61

10. Global Market Perspective II-63
Table 8: World Recent Past, Current & Future Analysis for
Antibiotics by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2000 through 2010 (includes corresponding Graph/Chart) II-63

Table 9: World Long-term Projections for Antibiotics by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) II-64

Table 10: World 10-Year Perspective for Antibiotics by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
and Rest of World Markets for Years 2003, 2008 & 2012
(includes corresponding Graph/Chart) II-65

Table 11: World Recent Past, Current & Future Analysis for
Penicillin by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2000 through 2010 (includes corresponding Graph/Chart) II-66

Table 12: World Long-term Projections for Penicillin by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) II-67

Table 13: World 10-Year Perspective for Penicillin by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Rest of World Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) II-68

Table 14: World Recent Past, Current & Future Analysis for
Cephalosporin by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) II-69

Table 15: World Long-term Projections for Cephalosporin by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) II-70

Table 16: World 10-Year Perspective for Cephalosporin by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Rest of World Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) II-71

Table 17: World Recent Past, Current & Future Analysis for
Macrolides by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2000 through 2010 (includes corresponding Graph/Chart) II-72

Table 18: World Long-term Projections for Macrolides by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) II-73

Table 19: World 10-Year Perspective for Macrolides by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Rest of World Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) II-74

Table 20: World Recent Past, Current & Future Analysis for
Quinolones by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2000 through 2010 (includes corresponding Graph/Chart) II-75

Table 21: World Long-term Projections for Quinolones by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) II-76

Table 22: World 10-Year Perspective for Quinolones by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Rest of World Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) II-77

Table 23: World Recent Past, Current & Future Analysis for
Carbapenems by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2000 through 2010 (includes corresponding Graph/Chart) II-78

Table 24: World Long-term Projections for Carbapenems by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) II-79

Table 25: World 10-Year Perspective for Carbapenems by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Rest of World Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) II-80

Table 26: World Recent Past, Current & Future Analysis for
Other Antibiotics by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) II-81

Table 27: World Long-term Projectionsfor Other Antibiotics by
Geographic Region - US, Canada, Jap an, Europe, Asia- Pacific
(excluding Japan), and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) II-82

Table 28: World 10-Year Perspective for Other Antibiotics by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and
Rest of World Markets for Years 2003, 2008 & 2012 (includes
corresponding Graph/Chart) II-83


III. MARKET

1. The United States III-1
A.Market Analysis III-1
Current and Future Analysis III-1
Antibiotics Approved Between 2000 and 2005 in the United
States III-1
Competition III-1
Table 29: Leading Players in the US Antibiotics Market
(2006): Percentage Breakdown by Value Sales for Pfizer,
Johnson & Johnson, GlaxoSmithKline, Abbott, and Others
(includes corresponding Graph/Chart) III-2
Strategic Corporate Developments III-2
Product Introductions/Innovations III-10
FDA Approvals / Patents III-12
Focus on Select Players III-16
B.Market Analytics III-20
Table 30: US Recent Past, Current & Future Analysis for
Antibiotics by Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-20

Table 31: US Long-term Projections for Antibiotics by
Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
MarketsIndependently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-21

Table 32: US 10-Year Perspective for Antibiotics by Product
Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides, Quinolones,
Carbapenems and Other Antibiotics Markets for 2003, 2008 &
2012 (includes corresponding Graph/Chart) III-22

2. Canada III-23
Market Analysis III-23
Current And Future Analysis III-23
Strategic Corporate Developments III-23
Product Introductions/Innovations III-24
Table 33: Canadian Recent Past, Current & Future Analysis
for Antibiotics by Product Segment - Penicillin,
Cephalosporin, Macrolides,Quinolones, Carbapenems and Other
Antibiotics Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-25

Table 34: Canadian Long-term Projections for Antibiotics by
Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-26

Table 35: Canadian 10-Year Perspective for Antibiotics by
Product Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides,Quinolones,
Carbapenems and Other Antibiotics Markets for 2003, 2008 &
2012 (includes corresponding Graph/Chart) III-27

3. Japan III-28
A.Market Analysis III-28
Current and Future Analysis III-28
Strategic Corporate Developments III-28
Product Introductions/Innovations III-31
Focus on Select Players III-32
B.Market Analytics III-35
Table 36: Japanese Recent Past, Current & Future Analysis
for Antibiotics by Product Segment - Penicillin,
Cephalosporin, Macrolides,Quinolones, Carbapenems and Other
Antibiotics Markets Independently Analyzed with Annual
Sales in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-35

Table 37: Japanese Long-term Projections for Antibiotics by
Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-36

Table 38: Japanese 10-Year Perspective for Antibiotics by
Product Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides, Quinolones,
Carbapenems and Other Antibiotics Markets for 2003, 2008 &
2012 (includes corresponding Graph/Chart) III-37

4. Europe III-38
A.Market Analysis III-38
Current and Future Analysis III-38
Strategic Corporate Developments III-38
B.Market Analytics III-40
Table 39: European Recent Past, Current & Future Analysis
for Antibiotics by Geographic Region - France, Germany,
Italy, UK, Spain, and Rest of Europe Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) III-40

Table 40: European Long-term Projections for Antibiotics by
Geographic Region - France, Germany, Italy, UK, Spain, and
Rest of Europe Markets Independently Analyzed with Annual
Sales in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-41

Table 41: European Recent Past, Current & Future Analysis
for Antibiotics by Product Segment - Penicillin,
Cephalosporin, Macrolides,Quinolones, Carbapenems, and Other
Antibiotics Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-42

Table 42: European Long-term Projections for Antibiotics by
Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems, and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-43

Table 43: European 10-Year Perspective for Antibiotics by
Geographic Region - Percentage Breakdown of Dollar Sales for
France, Germany, Italy, UK, Spain, and Rest of Europe
Markets for 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-44

Table 44: European 10-Year Perspective for Antibiotics by
Product Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides, Quinolones,
Carbapenems, and Other Antibiotics Markets for 2003, 2008 &
2012 (includes corresponding Graph/Chart) III-45

4a. France III-46
A.Market Analysis III-46
Current and Future Analysis III-46
Trends III-46
Over Consumption of Antibiotics - Cause of Concern III-46
Strategic Corporate Developments III-47
Sanofi-Aventis SA - A Key Player III-47
B.Market Analytics III-48
Table 45: French Recent Past, Current & Future Analysis for
Antibiotics by Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-48

Table 46: French Long-term Projections for Antibiotics by
Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-49

Table 47: French 10-Year Perspective for Antibiotics by
Product Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides, Quinolones,
Carbapenems and Other Antibiotics Markets for2003, 2008 &
2012 (includes corresponding Graph/Chart) III-50

4b. Germany III-51
A.Market Analysis III-51
Current and Future Analysis III-51
Strategic Corporate Developments III-51
Bayer HealthCare AG - A Key Player III-52
B.Market Analytics III-53
Table 48: German Recent Past, Current & Future Analysis for
Antibiotics by Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-53

Table 49: German Long-term Projections for Antibiotics by
Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-54

Table 50: German 10-Year Perspective for Antibiotics by
Product Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides,Quinolones,
Carbapenems and Other Antibiotics Markets for 2003, 2008 &
2012 (includes corresponding Graph/Chart) III-55

4c. Italy III-56
A.Market Analysis III-56
Current and Future Analysis III-56
Corporate Development III-56
B.Market Analytics III-57
Table 51: Italian Recent Past, Current & Future Analysis for
Antibiotics by Product Segment - Penicillin, Cephalosporin,
Macrolides, Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-57

Table 52: Italian Long-term Projections for Antibiotics by
Product Segment - Penicillin, Cephalosporin, Macrolides,
Quinolones, Carbapenems and Other Antibiotics Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding Graph/Chart) III-58

Table 53: Italian 10-Year Perspective for Antibiotics by
Product Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides,Quinolones,
Carbapenems and Other Antibiotics Markets for 2003, 2008 &
2012 (includes corresponding Graph/Chart) III-59

4d. The United Kingdom III-60
Market Analysis III-60
Current And Future Analysis III-60
Product Introduction III-60
GlaxoSmithKline Plc - A Key Player III-60
Table 54: UK Recent Past, Current & Future Analysis for
Antibiotics by Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-61

Table 55: UK Long-term Projections for Antibiotics by
Product Segment - Penicillin, Cephalosporin, acrolides,
Quinolones, Carbapenems and Other Antibiotics Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2011 through 2015 (includes corresponding
Graph/Chart) III-62

Table 56: UK 10-Year Perspective for Antibiotics by Product
Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides, Quinolones,
Carbapenems and Other Antibiotics Markets for2003, 2008 &
2012 (includes corresponding Graph/Chart) III-63

4e. Spain III-64
Market Analysis III-64
Table 57: Spanish Recent Past, Current & Future Analysis for
Antibiotics by Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-64

Table 58: Spanish Long-term Projections for Antibiotics by
Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-65

Table 59: Spanish 10-Year Perspective for Antibiotics by
Product Segment - Percentage Breakdown of Dollar Sales for
Penicillin, Cephalosporin, Macrolides, Quinolones,
Carbapenems and Other Antibiotics Markets for 2003, 2008 &
2012 (includes corresponding Graph/Chart) III-66

4f. Rest of Europe III-67
A.Market Analysis III-67
Current and Future Analysis III-67
Strategic Corporate Developments III-67
Product Launch III-69
Focus on Select Players III-69
B.Market Analytics III-71
Table 60: Rest of Europe Recent Past, Current & Future
Analysis for Antibiotics by Product Segment - Penicillin,
Cephalosporin, Macrolides,Quinolones, Carbapenems and Other
Antibiotics Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-71

Table 61: Rest of Europe Long-term Projections for
Antibiotics by Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-72

Table 62: Rest of Europe 10-Year Perspective for Antibiotics
by Product Segment - Percentage Breakdown of Dollar Sales
for Penicillin, Cephalosporin, Macrolides,Quinolones,
Carbapenems and Other Antibiotics Markets for 2003, 2008 &
2012 (includes corresponding Graph/Chart) III-73

5. Asia-Pacific III-74
A.Market Analysis III-74
Current and Future Analysis III-74
India III-74
Rising Prices of Penicillin G to Affect Antibiotics
Production III-74
Strategic Corporate Developments III-74
Product Introduction III-79
FDA Approvals / Patents III-79
Focus on Select Players III-79
B.Market Analytics III-81
Table 63: Asia-Pacific Recent Past, Current & Future
Analysis for Antibiotics by Product Segment - Penicillin,
Cephalosporin, Macrolides,Quinolones, Carbapenems and Other
Antibiotics Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-81

Table 64: Asia-Pacific Long-term Projections for Antibiotics
by Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-82

Table 65: Asia-Pacific 10-Year Perspective for Antibiotics
by Product Segment - Percentage Breakdown of Dollar Sales
for Penicillin, Cephalosporin, Macrolides, Quinolones,
Carbapenems and Other Antibiotics Markets for 2003, 2008 &
2012 (includes corresponding Graph/Chart) III-83

6. Rest of World III-84
A.Market Analysis III-84
Current and Future Analysis III-84
Strategic Corporate Developments III-84
B.Market Analytics III-85
Table 66: Rest of World Recent Past, Current & Future
Analysis for Antibiotics by Product Segment - Penicillin,
Cephalosporin, Macrolides,Quinolones, Carbapenems and Other
Antibiotics Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-85

Table 67: Rest of World Long-term Projections for
Antibiotics by Product Segment - Penicillin, Cephalosporin,
Macrolides,Quinolones, Carbapenems and Other Antibiotics
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-86

Table 68: Rest of World 10-Year Perspective for Antibiotics
by Product Segment - Percentage Breakdown of Dollar Sales
for Penicillin, Cephalosporin, Macrolides,Quinolones,
Carbapenems and Other Antibiotics Markets for 2003, 2008 &
2012 (includes corresponding Graph/Chart) III-87


IV. COMPETITIVE LANDSCAPE